Zobrazeno 1 - 10 of 56 pro vyhledávání: '"Enadenotucirev"'
1
Akademický článek
A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE)
Autor: Jean-Pascal Machiels, Ramon Salazar, Sylvie Rottey, Ignacio Duran, Luc Dirix, Karen Geboes, Christine Wilkinson-Blanc, Gillian Pover, Simon Alvis, Brian Champion, Kerry Fisher, Hilary McElwaine-Johnn, John Beadle, Emiliano Calvo
Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-15 (2019)
Abstract Background Enadenotucirev is a chimeric adenovirus with demonstrated preclinical tumor-selective cytotoxicity and a short half-life. Further clinical mechanism of action data showed that enadenotucirev can gain access to and replicate within
Externí odkaz: https://doaj.org/article/26c0983875fa4d0da5e0fc2f0a11a2aa
Zobrazit plný text záznamu
2
Akademický článek
Preclinical Safety Studies of Enadenotucirev, a Chimeric Group B Human-Specific Oncolytic Adenovirus
Autor: Sam Illingworth, Ying Di, Maxine Bauzon, Janet Lei, Margaret R. Duffy, Simon Alvis, Brian Champion, André Lieber, Terry Hermiston, Len W. Seymour, John Beadle, Kerry Fisher
Publikováno v: Molecular Therapy: Oncolytics, Vol 5, Iss C, Pp 62-74 (2017)
Enadenotucirev is an oncolytic group B adenovirus identified by a process of bio-selection for the ability to selectively propagate in and rapidly kill carcinoma cells. It is resistant to inactivation by human blood components, potentially enabling i
Externí odkaz: https://doaj.org/article/a7c13d435d3b499f8c2068ee8f9375b9
Zobrazit plný text záznamu
3
Attenuation of the Hypoxia Inducible Factor Pathway after Oncolytic Adenovirus Infection Coincides with Decreased Vessel Perfusion
Autor: Egon J. Jacobus, Jakob Kaeppler, Iris Yousaf, Sally Frost, Len Seymour
Publikováno v: Cancers
Cancers, Vol 12, Iss 851, p 851 (2020)
Volume 12
Issue 4
The interplay between oncolytic virus infection and tumour hypoxia is particularly unexplored in vivo, although hypoxia is present in virtually all solid carcinomas. In this study, oncolytic adenovirus infection foci were found within pimonidazole-re
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::58dd2a343962e805fddd8c8e81588948
http://europepmc.org/articles/PMC7225929
Zobrazit plný text záznamu
4
342 Combining enadenotucirev and nivolumab increased tumour immune cell infiltration/activation in patients with microsatellite-stable/instability-low metastatic colorectal cancer in a phase 1 study
Autor: Hani M. Babiker, Lee S. Rosen, Ding Wang, Jordan Berlin, Richard J. C. Brown, David Krige, Marwan Fakih, Tom Lillie, David Miles, Jo Carter, Minesh Patel, Gianfranco Di Genova, Wael A. Harb, Mark Powell
Publikováno v: Journal for ImmunoTherapy of Cancer. 9:A368-A369
BackgroundMicrosatellite-stable (MSS) and instability-low (MSI-L) metastatic colorectal cancer (mCRC) are typically characterised as ”immune-excluded/desert” tumour microenvironments lacking T-cell infiltration. Anti-PD-1 monotherapy has little c
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7987db10990a98ea69aa72925db95d5c
https://doi.org/10.1136/jitc-2021-sitc2021.342
Zobrazit plný text záznamu
5
A phase 1 trial of the safety, tolerability and biological effects of intravenous Enadenotucirev, a novel oncolytic virus, in combination with chemoradiotherapy in locally advanced rectal cancer (CEDAR)
Autor: Maria A. Hawkins, Jane Holmes, David Sebag-Montefiore, Tim Maughan, J. Good, Kerry D. Fisher, Steven Davis, Leonard W. Seymour, Richard J. C. Brown, Richard Adams, Sean M. O'Cathail
Publikováno v: Radiation Oncology (London, England)
Radiation Oncology, Vol 15, Iss 1, Pp 1-8 (2020)
Background Chemoradiotherapy remains the standard of care for locally advanced rectal cancer. Efforts to intensify treatment and increase response rates have yet to yield practice changing results due to increased toxicity and/or absence of increased
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e18bb7396ab52aee2f05a3681a7e73cf
https://doi.org/10.1186/s13014-020-01593-5
Zobrazit plný text záznamu
6
A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE)
Autor: Christine Wilkinson-Blanc, Ramon Salazar, Ignacio Duran, Kerry D. Fisher, Simon Alvis, Karen Geboes, Emiliano Calvo, Hilary McElwaine-Johnn, Sylvie Rottey, Gillian Pover, John William Beadle, Brian R. Champion, Luc Dirix, Jean-Pascal Machiels
Publikováno v: Journal for Immunotherapy of Cancer
Digital.CSIC. Repositorio Institucional del CSIC
instname
JOURNAL FOR IMMUNOTHERAPY OF CANCER
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-15 (2019)
Dipòsit Digital de la UB
Universidad de Barcelona
[Background] Enadenotucirev is a chimeric adenovirus with demonstrated preclinical tumor-selective cytotoxicity and a short half-life. Further clinical mechanism of action data showed that enadenotucirev can gain access to and replicate within differ
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2033338b56bbb71a2a23187410b024d0
https://ora.ox.ac.uk/objects/uuid:a376bcd1-88f4-4b2a-81fc-e95acfcb3230
Zobrazit plný text záznamu
7
External Beam Radiation Therapy and Enadenotucirev: Inhibition of the DDR and Mechanisms of Radiation-Mediated Virus Increase
Autor: Egon J. Jacobus, William K. Taverner, Arthur Dyer, Tzveta D. Pokrovska, Kerry D. Fisher, Janet Lei-Rossmann, Katharine J. Herbert, Richard Baugh, Geoff S. Higgins, Gonzalo Rodriguez-Berriguete, Rathi Puliyadi, Remko Prevo, Brian R. Champion, Len Seymour, Giovanna Granata, Sally Frost
Publikováno v: Cancers
Volume 12
Issue 4
Cancers, Vol 12, Iss 4, p 798 (2020)
Ionising radiation causes cell death through the induction of DNA damage, particularly double-stranded DNA (dsDNA) breaks. Evidence suggests that adenoviruses inhibit proteins involved in the DNA damage response (DDR) to prevent recognition of double
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d2b663461da094fc8688fc3579b265e7
http://europepmc.org/articles/PMC7226394
Zobrazit plný text záznamu
8
NK cells augment oncolytic adenovirus cytotoxicity in ovarian cancer
Autor: Jaya Nautiyal, Daniel M. Davis, Iain A. McNeish, Malcolm Farquharson, Sophie McNamara, Kerry D. Fisher, Christopher A.H. Hansell, Darren Ennis, Elaine Y.L. Leung, Philippa R. Kennedy, Suzanne Dowson, Leo M. Carlin, Pavlina Spiliopoulou, Gerard J. Graham
Publikováno v: Molecular Therapy: Oncolytics, Vol 16, Iss, Pp 289-301 (2020)
Molecular Therapy Oncolytics
Oncolytic viruses (OVs) can trigger profound innate and adaptive immune responses, which have the potential both to potentiate and reduce the activity of OVs. Natural killer (NK) cells can mediate potent anti-viral and anti-tumoral responses, but the
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b1a8072a8f57405e92659ef39098dd8
http://hdl.handle.net/10044/1/77780
Zobrazit plný text záznamu
9
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
10
Group B adenovirus enadenotucirev infects polarised colorectal cancer cells efficiently from the basolateral surface expected to be encountered during intravenous delivery to treat disseminated cancer
Autor: Arthur Dyer, Kerry D. Fisher, David J. P. Ferguson, Suet Lin Chia, Janet Lei, Leonard W. Seymour
Publikováno v: Virology. 505:162-171
Enadenotucirev (EnAd) is a group B oncolytic adenovirus developed for systemic delivery and currently undergoing clinical evaluation for advanced cancer therapy. For differentiated carcinomas, systemic delivery would likely expose virus particles to
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db2ada363bbf44fe8c6f0611ea96c66f
https://doi.org/10.1016/j.virol.2017.02.011
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje